SCHEMBL7051579

SCHEMBL7051579

Cc1cc(NC(=N)N)nc2ccc3ccccc3c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
TYMS P04818 2/20 0.40
LMNA P02545 6/20 0.39
MAPT P10636 6/20 0.39
HPGD P15428 5/20 0.39
HTT P42858 4/20 0.39
GAA P10253 3/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
KDM4E B2RXH2 7/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
POLB P06746 1/20 0.38
HSP90AA1 P07900 1/20 0.38
PKM P14618 1/20 0.38
GRK6 P43250 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7054045 0.82 KDM4E (0.54) ALDH1A1RAB9ANPC1CYP1A2LMNA
SCHEMBL7055081 0.77 MEN1 (0.45) ALDH1A1MAPTHPGDKMT2AMEN1
SCHEMBL4824353 0.76 TYMS (0.41) ALDH1A1RAB9ANPC1CYP3A4CYP1A2
SCHEMBL7056158 0.75 KMT2A (0.56) ALDH1A1RAB9ANPC1CYP3A4CYP1A2
SCHEMBL7057382 0.75 ELANE (0.35) ALDH1A1RAB9ANPC1LMNAMAPT
SCHEMBL8571951 0.74 CYP1A2 (0.58) ALDH1A1RAB9ANPC1CYP3A4CYP1A2
SCHEMBL7057628 0.73 ALDH1A1 (0.67) ALDH1A1RAB9ANPC1LMNAMAPT
SCHEMBL7052739 0.72 F2 (0.48) ALDH1A1MAPTHPGDGAAKMT2A
SCHEMBL7056248 0.72 KMT2A (0.46) ALDH1A1RAB9ACYP1A2LMNAMAPT
SCHEMBL7059022 0.71 ALDH1A1 (0.47) ALDH1A1RAB9ANPC1CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176314-A1 Compounds for the treatment of pain H. LUNDBECK A/S (DK) 2003-09-18 US disclosed
US-20030139431-A1 Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors H. LUNDBECK A/S (DK) 2003-07-24 US disclosed
WO-2003026657-A1 COMPOUNDS FOR THE TREATMENT OF PAIN SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2003-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176314-A1 Compounds for the treatment of pain NPFFR2, NPFFR1, OPRL1 ALDH1A1 390/4885RAB9A 3568/4885NPC1 1526/4885
US-20030139431-A1 Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors NPFFR1, NPFFR2, SSTR3 ALDH1A1 3738/4885RAB9A 2019/4885NPC1 708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.